Mobidiag, a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, has announced exclusive agreements with international partners for the distribution of its Amplidiag and Novodiag products in Europe and the Middle East.
Tuomas Tenkanen (Mobidiag CEO) said: “We are extremely pleased to have further expanded our commercial footprint into additional international territories. Our highly ersatile and complementary Amplidiag and Novodiag diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate and affordable diagnostic solutions to a wide range of infectious diseases.”
